#NRG2024 Summer Meeting in Denver | |
Join us for the NRG Oncology Summer Meeting July 25-27, 2024, at the Sheraton Denver Downtown Hotel in Denver, CO. The Meeting will be held in-person (with limited virtual session offerings). | |
#NRG2024 Featured Sessions | |
|
Social Media Workshop – Virtual Session
The NRG Oncology Communications Committee is pleased to announce our Social Media Workshop as part of #NRG2024. The workshop, being held as a virtual session, is scheduled for Monday, July 22, 2024, 10-11am EDT (8-9am MDT). Drs. Kristin Higgins and Miriam Knoll, members of the NRG Oncology Communications Committee, are the workshop chairs. The session speakers include Dr. Amy Comander from Massachusetts General Hospital; she will be discussing advocacy and lifestyle medicine; Dr. Stephen Chun from MD Anderson and Dr. Lauren Henke from University Hospitals/Case Western University will be presenting about NRG’s new Podcast Project. View the session flyer for details!
| |
|
Summer 2024 Symposium “Novel, Next and Now: Checkpoint Inhibitors and Cellular Immunotherapy Progress in Oncology”
Join us in-person or virtually! Thursday, July 25, 2024, 8am to 12pm MDT. Speakers will focus their presentations on the current state of immunotherapy focusing on gynecologic malignancies, future immunotherapy options beyond checkpoint inhibitors with lessons learned from non-gynecologic malignancies, and how to establish successful phase I and cellular therapy teams in both academic and community settings. View the symposium flyer for details!
| |
|
Head & Neck Cancer Symposium
We are thrilled to announce our new Head & Neck Cancer Symposium at #NRG2024 in Denver! This all-you-need-to-know session on toxicities affecting head and neck cancer patients is being held on Thursday, July 25 and will be chaired by Dr. Sue Yom, NRG Head & Neck Cancer Committee Chair and Dr. Mitch Machtay, NRG Deputy Group Chair (Research). Check out the presenters & topics here!
| |
|
NRG Oncology Protocol Support Committee (PSC) – Educational Sessions
Please be sure to sign up to attend the PSC Sessions being held during the NRG Oncology Summer Meeting in Denver. The PSC will host a Continuing Education session and Roundtable presentations on Thursday, July 25; and a Protocol Spotlight Session (NRG-CC011, NRG-GI008, NRG-BR008) on Friday, July 26. Please refer to the session flyers and agendas (login required) for more details about the PSC programing offered at #NRG2024. The PSC programming at #NRG2024 has been approved by the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
| |
|
#NRG2024 Session Flyers
Promotional flyers for #NRG2024 Meeting sessions are available on the NRG website.
| |
|
The Advocate Angle
*A new segment in NRG Currents created by our Patient Advocate Committee*
| |
NRG’s Data Monitoring Committee: Through the Lens of an Advocate | |
Article by Lisa Taylor an NRG Oncology Patient Advocate on the Data Management Committee (DMC) | |
NRG’s Data Management Committee (DMC) reviews NRG trials in progress to make sure that continuing a trial is both scientifically sound and ethically responsible. Based on that review, the DMC makes a recommendation to the NRG Group Chairs to continue, terminate, or pause a trial; the ultimate decision is made by those Group Chairs. To me, the DMC helps deliver relevant trials, executed safely, without undue delay. | |
Protocol Support Committee (PSC) Column | |
Written and submitted by Judith O. Hopkins, MD, SCOR Principal Investigator, Novant Health Cancer Institute - Kernersville | |
Cancer doesn’t care who you are, what occupation you have or what type of lifestyle you lead. Cancer is an “equal opportunity” disease. Cancer first entered our lives 14 years ago when my husband was diagnosed with chronic lymphocytic leukemia (CLL) and started chemotherapy. As an oncologist, I was all too familiar with the side effects of chemotherapy induced fever, chills, neutropenia and fatigue. There were prophylactic antibiotics and frequent office visits. Friends made a huge difference with my husband’s therapy, sitting with him and transporting him home after therapy was completed. | |
|
NRG Study News & New Protocols Under Development | |
NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial | |
NRG-CC011 activated on February 2, 2024, and is OPEN to accrual. Sites are being approved to participate and beginning to enroll participants to the study. Our goal is to recruit 386 breast cancer survivors with substantial cognitive concerns. We encourage all sites, especially our community and minority sites, to join our study to address cancer related cognitive impairment.
To minimize site burden: a Screening Script is available on the CTSU website under NRG-CC011 – CIRB Approved Documents Support Documents – Screening Script (Version 11/30/23) which will streamline your review of potentially eligible participants. The script will save you and the potential participant time -- ask participants if they have cognitive concerns and are interested in the study – if yes, proceed with verbal consent to complete the screening questionnaires; if the answer is no, you should not proceed with verbal consent or further screening.
| |
|
Study Participation Survey for NRG-BR008/The HERO Study
The NRG-BR008/HERO Study Team would like to understand more about the obstacles your site is facing in enrolling patients to the NRG-BR008 study.
In addition, if your site has not opened the NRG-BR008 study, we also want to learn the reasons for your choice.
Please scan the QR code to take this short, 1-question survey so we can better appreciate your challenges and consider potential solutions.
| |
|
NRG-BR008/HERO Workshop at NRG2024
Please join NRG-BR008 study PIs, Drs. Lior Braunstein and Melissa Mitchell for the NRG-BR008/HERO Study Workshop being held on July 27 at NRG2024 in Denver. For more information about this workshop and other BR008 sessions, please view the flyer posted here.
| |
New Protocols Under Development | |
NCORP Neurocognitive Workshop Webinar | |
|
The NRG NCORP Research Base is hosting a Neurocognitive Workshop webinar on Monday, July 15; 4-5:30pm EDT. Presenters will discuss new and ongoing NRG trials to mitigate neurocognitive changes, explore implementation science in areas where NRG trials have changed clinical care guidelines and discuss ways to build upon previous NRG trials related to neurocognitive preservation during or after cancer. The flyer with agenda can be found here.
There is still time to register in advance for this workshop: https://bit.ly/NCORPWorkshop. After registering you will receive an email with the link to join the webinar.
| |
SOROCk on Social Media: An Ovarian Cancer Prevention Trial for carriers of a BRCA1 mutation | |
Have you been following NRG Oncology’s social media campaign for the SOROCk (NRG-CC008) study? Every Wednesday is SOROCk’n Wednesday on NRG Oncology’s X, Instagram, Facebook, and LinkedIn accounts. We would like to thank the SOROCk Study Team for their help in promoting this important clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers. Visit the SOROCk page on the NRG Oncology website for more information. | |
FORTE enrolled its 1700th participant on July 3, 2024, less than a month after enrolling the 1600th participant!
| |
FORTE Coordinator Session - August 7, 2024 | |
Mei-Yin Polley, PhD, Promoted to Full Professor at the University of Chicago
| |
Dr. Mei-Yin Polley has been promoted to Full Professor in the Department of Public Health Sciences at the University of Chicago. Dr. Polley joined NRG Oncology Statistics and Data Management Center (SDMC) in 2020 and has since held positions as the Head of Statistics Division of SDMC and the Lead Statistician for the Brain Tumor Committee for NRG Oncology. | |
NRG Oncology Investigators Inductees of Giants of Cancer Care 12th Annual Recognition Program | |
The Giants of Cancer Care® recognition program celebrates the achievements of leading researchers and educators whose discoveries have helped propel the field forward and established the building blocks for future advances. A Selection Committee of 120+ eminent oncologists choose honorees from several different tumor types and specialty categories. Inductees are announced in the Spring each year. | |
|
This year’s NRG inductees are:
Breast Cancer: Joseph A. Sparano, MD –The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
Gastrointestinal Cancer: John L. Marshall, MD —The Ruesch Center for the Cure of Gastrointestinal
Genitourinary Cancer: Christopher J. Logothetis, MD —The University of Texas MD Anderson Cancer Center
Gynecologic Cancer: Carol A. Aghajanian, MD —Memorial Sloan Kettering Cancer Center
Radiation Oncology: Ralph R. Weichselbaum, MD —The University of Chicago Medicine
The awards ceremony took place on Thursday, May 30, 2024, at the Adler Planetarium in Chicago, Illinois. Read more
| |
|
NRG PAC member shares cancer survivorship story on international level
Other countries are taking notice of how important cancer survivorship and patient advocacy impacts patient lives. NRG Patient Advocate Committee member, Wenora Johnson’s cancer survivorship story and advocacy work for patients’ rights was featured in an article shared in the Swiss newspaper, NZZ Global Reporting from Switzerland. Click here to read the full article.
| |
|
|
Congratulations to NRG PAC Members-Scholarship recipients!
NRG Oncology Patient Advocate Committee members, Marlyn Molero and Rubilez Bolivar, were recently awarded Vituity's annual Dr. Laura Cook Scribe Scholarships to help further their education in medicine. Read more.
| | | | |
